Cocrystal Pharma Files 8-K

Ticker: COCP · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1412486

Cocrystal Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyCocrystal Pharma, INC. (COCP)
Form Type8-K
Filed DateJun 20, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, sec-filing

TL;DR

Cocrystal Pharma filed an 8-K on 6/20/24 with routine corporate disclosures.

AI Summary

Cocrystal Pharma, Inc. filed an 8-K on June 20, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's corporate information, including its address in Bothell, WA, and its fiscal year end of December 31. It also lists former company names and dates of name changes.

Why It Matters

This filing provides routine corporate updates and disclosures required by the SEC, offering transparency to investors about the company's structure and reporting status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K with no new material financial information or significant corporate events disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, covering Regulation FD Disclosure and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 20, 2024.

In which state is Cocrystal Pharma, Inc. incorporated?

Cocrystal Pharma, Inc. is incorporated in Delaware.

What is the principal executive office address for Cocrystal Pharma, Inc.?

The principal executive office address is 19805 N. Creek Parkway, Bothell, WA 98011.

What were some of Cocrystal Pharma's former company names?

Cocrystal Pharma's former company names include BIOZONE PHARMACEUTICALS, INC. (name change date: 20110304) and International Surf Resorts, Inc. (name change date: 20070917).

Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-06-20 08:30:41

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 20, 2024 Cocrystal Pharma, Inc. By: /s/James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing